H19 and steatosis: We will discuss dysregulation of H19 in the progression of liver-related diseases, including steatosis, fibrosis, cirrhosis, diabetes, and hepatocellular carcinoma (HCC) with a particular focus on the epithelial to mesenchymal transition (EMT).